US FDA Approves Mirum Rare Bone Drug
The US Food and Drug Administration has approved Mirum Pharmaceuticals drug to treat a rare bone disorder. The regulatory decision was announced on Friday.
Xurve View
Insights:
Xurve View
Mirum Pharmaceuticals Inc won United States Food and Drug Administration approval for its therapy targeting a rare bone disorder, the regulator announced on Friday afternoon. The clearance expands the company's rare-disease portfolio following clinical trials. Investors have closely watched the regulatory decision as a key revenue driver for the drugmaker.
